Skin Cancer Detection in Primary Care With and Without DermaSensor (INSIGHT-RCT)
Improving Skin Cancer Detection With AI-Assisted Triage in Healthcare: A Real-World, Multi-Center, Randomized Controlled Trial (INSIGHT-RCT)
This randomized controlled trial evaluates whether primary care physician access to the DermaSensor device increases the proportion of patients with histopathology-confirmed skin cancer compared with physician standard clinical assessment alone. Participating physicians are randomized and outcomes are drawn from existing electronic health record data for up to 500,000 patient encounters.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Justin Frazier, MS
- 電話番号:508-776-0044
- メール:justin.frazier@dermasensor.com
研究場所
-
-
Missouri
-
St Louis、Missouri、アメリカ、63131
- SSM Health
-
コンタクト:
- Margaret Scott
- 電話番号:716-310-6140
- メール:mscott@circuitclinical.com
-
主任研究者:
- Joseph Eckelkamp, Jr., MD
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Practicing primary care provider in the labeled user population for the DermaSensor device (per the Instructions for Use)
- Practicing at a participating site that uses an EMR system modifiable at the user level
- Practicing at a participating site that routinely documents skin check data, including coding for skin checks and lesion diagnoses
- Practicing at a participating site where pathology results for patients referred to dermatology are routinely accessible for study analyses
Exclusion Criteria:
- Not actively practicing in primary care at a participating study site
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Unaided standard care
Primary care clinics continuing routine assessment of skin lesions without access to the DermaSensor device. |
|
|
実験的:DermaSensor-aided care
Primary care clinics with access to the DermaSensor device as an adjunct to clinical assessment of skin lesions. |
Handheld device used by primary care physicians as an adjunct to clinical assessment of skin lesions suggestive of skin cancer, per its labeling. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with histopathology-confirmed skin cancer
時間枠:Within 12 months of the initial primary care visit
|
Proportion of all patients seen by participating primary care physicians with a skin cancer (melanoma, basal cell carcinoma, or squamous cell carcinoma) confirmed by histopathology within 12 months of the initial visit, compared between device-aided and unaided physicians. |
Within 12 months of the initial primary care visit
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number needed to refer or biopsy (NNRB)
時間枠:Within 12 months of the initial primary care visit
|
Proportion of biopsies returning a malignant result and proportion of dermatology referrals returning a malignant result, compared between device-aided and unaided physicians. |
Within 12 months of the initial primary care visit
|
|
Skin cancers identified after a Monitor result or non-referral decision
時間枠:Within 12 months of the initial primary care visit
|
Skin cancers confirmed during follow-up after an initial device Monitor result or a non-referral/non-biopsy decision, with stage and severity characterized, compared between groups. |
Within 12 months of the initial primary care visit
|
|
Change in skin cancer detection rate among device physicians
時間枠:From pre-device baseline period through study completion
|
Rate of change in skin cancer detection among physicians using the device, compared with the same physicians before device access, the unaided arm, and non-user physicians in the device arm. |
From pre-device baseline period through study completion
|
|
Time to biopsy or dermatologist evaluation and to treatment
時間枠:Within 12 months of the initial primary care visit
|
Interval from initial primary care presentation to (1) biopsy or dermatologist evaluation and (2) treatment of the skin lesion, compared between groups. |
Within 12 months of the initial primary care visit
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CSP-25-0002-B
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。